ADMA: ADMA Biologics Growth-Adjusted Market Cap to Net Income

The ADMA Biologics (ADMA) PEG ratio chart illustrates the asset's valuation dynamics, where the metric stands at 0.75. The company's revenues are based on the sale of immunoglobulins and plasma collection. Its proprietary donation centers minimize raw material risks within a stringent regulatory environment. Growing demand for medications for immunodeficient patients is driving the expansion of both the customer base and production capacities.

The PEG ratio relates the market value of earnings to their growth rate, allowing for the determination of an asset's fair value considering future expansion. By analyzing the P/E ratio relative to the company's growth rates, an investor identifies business undervaluation, which is critically important for ADMA Biologics as it scales its plasma collection center network and commercializes patented immunoglobulins.